The collection reads as a science-forward discussion about a head-to-head trial comparing tirzepatide to semaglutide. Participants repeatedly highlight greater HbA1c reduction and weight loss with tirzepatide, reference SURPASS-2 NEJM data, and contrast safety profiles. Language ranges from enthusiastic endorsements to cautious notes about adverse events, reflecting a generally favorable but still exploratory stance on adopting the newer dual GLP-1/GIP agonist in diabetes management.
AgreementModerate agreement
Most posts express positive or neutral agreement that tirzepatide performs well against semaglutide, often citing NEJM SURPASS-2 results and weight/HbA1c benefits.
InterestHigh interest
High overall interest; many posts discuss specific data points, trial names, and clinical implications rather than generic statements.
EngagementModerate engagement
Moderate engagement; several posts quote results, share opinions, or ask questions, but few show deep critical analysis or counterpoints.
ImpactModerate impact
Moderate impact; posts present the trial as promising and potentially practice-changing, but few discuss limitations or safety concerns in depth.
Abstract in brief
Tirzepatide is being tested for treating type 2 diabetes and compared to semaglutide to assess its effectiveness and safety.
In a 40-week trial with nearly 1,900 participants, different doses of tirzepatide were shown to reduce glycated hemoglobin levels more than semaglutide.
All doses of tirzepatide led to better body weight loss and similar mild to moderate gastrointestinal side effects compared to semaglutide, with rare instances of severe hypoglycemia.
A healthier future through pharmacotherapy awaits.
Sources:
https://t.co/x9J75jdSsP (P.S., SURPASS-5 was even more optimistic: https://t.co/N6dvG6Acjm)
https://t.co/z0m0Bagx2y
https://t.co/0qcNnNDMNA
https://t.co/fp0CvBOeso
https://t.co/daJovuxe8D
More:
@NeilFlochMD A mostly very good summary except for “There are no head-to-head studies comparing semaglutide and tirzepatide” SURPASS-2 is H2H #T2D
https://t.co/4mdsFCLrU2
May 2, 2023 · 25 likes · 1 share · 34,083 followersView post →
RL
Rohit Loomba
@DrLoomba · X
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/rUdsG6mZBq
Tirzepatide appears to be superior than Semaglutide on weight loss and HbA1c reductions
Good evidence of weight loss and HbA1c lowering with #Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 #Diabetes. https://t.co/UrUYYIrqKR
Jun 26, 2021 · 16 likes · 2 shares · 11,548 followersView post →
Insulin acts as a neurohormone influencing brain regions linked to emotion. This video explores how Mounjaro and GLP1 agonists impact emotional regulation, neurotransmitter production, and mental health, highlighting…
Tirzepatide is being tested for treating type 2 diabetes and compared to semaglutide to assess its effectiveness and safety. In a 40-week trial with nearly 1,900 participants, different doses of tirzepatide reduced…
Mounjaro and female fertility is an increasingly discussed topic, especially among women dealing with insulin resistance, obesity, and metabolic imbalances. This video explains how Mounjaro influences fertility…
Obesity is a significant health issue globally. A Phase 3 trial shows tirzepatide, a new medication, leads to substantial weight loss—up to 20.9%—over 72 weeks in adults with BMI 30 or higher.
Tirzepatide is being tested for treating type 2 diabetes and compared to semaglutide to assess its effectiveness and safety. In a 40-week trial with nearly 1,900 participants, different doses of tirzepatide were shown…
The numbers, straight:
SURMOUNT-1: weight down about 21% at 72 weeks, no diabetes.
SURPASS-2, head to head: beat semaglutide on blood sugar and weight.
Source: https://t.co/c655hoSN82
Source: https://t.co/2Zu30WPAYQ
The papers, so you do not have to take our word for it:
N Engl J Med 2022: 10.1056/NEJMoa2206038
N Engl J Med 2021: 10.1056/NEJMoa2107519
Lancet 2021: 10.1016/S0140-6736(21)01443-4
Ficha bibliográfica
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. doi:10.1056/NEJMoa2107519
Peptide study spotlight: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Human study coverage from The New England journal of medicine (2021) https://t.co/nIbBfUrLQz
Mar 27, 2026 · 6 likes · 1 share · 12,158 followersView post →
豊ザ
豊胸・脂肪吸引のショウ先生｜美しいボディラインを創る医学博士_THE CLINIC(ザクリニック)
@theclinicnishi · X
New England Journal of Medicine（とても凄い、医学の指針を決めるような学術雑誌）に2021年に掲載されたSURPASS2試験の結果が元になってますね。
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/ZcL1wAMKBv
A healthier future through pharmacotherapy awaits.
Sources:
https://t.co/x9J75jdSsP (P.S., SURPASS-5 was even more optimistic: https://t.co/N6dvG6Acjm)
https://t.co/z0m0Bagx2y
https://t.co/0qcNnNDMNA
https://t.co/fp0CvBOeso
https://t.co/daJovuxe8D
More:
✅ https://t.co/9xbiBzuptA
✅ https://t.co/VZkUA2HgN5
✅ https://t.co/pbaAzWfBWA
✅ https://t.co/EgJ07jp9XD
Turns out Tirzepatide can fix a lot of problems! Yay science! https://t.co/JlYxXoWA2t
【マンジャロ vs リベルサス──“本当に痩せやすい薬“はどっち？】
今回は、チルゼパチド（マンジャロ／ゼップバウンド）とセマグルチド（オゼンピック／ウゴービ／リベルサス）、どちらが“本当に痩せる”のか、さらには“副作用に違いはあるのか”──を医学的根拠に基づきながら徹底解説していきます！ https://t.co/92GwmleMuN
May 5, 2025 · 10 likes · 1 share · 2,674 followersView post →
ち薬
ちろ剤師★薬物療法ニキ
@Toki_nd2525 · X
これか SURPASS 2 trial
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/wKxMCth0aL
Mar 30, 2025 · 5 likes · 1 share · 7,038 followersView post →
B
beatifica
@VisIntellectus · X
@intronexon @IterIntellectus This is supported by the fact that other Ozempic-style drugs like Tirzepatide have significantly worse side-effects that Ozempic but are more "effective" in reducing weight and reducing hemoglobin levels.
https://t.co/UrvpJXUWYr
@bryan_johnson For Retatrutide, a newer triple agonist (GLP-1, GIP, and glucagon), direct comparative studies with semaglutide or Tirzepatide are not yet as widely available in published literature, as it is still undergoing clinical trials.
Reference:
Frías, J. P., Davies, M. J., Rosenstock,
Oct 29, 2024 · 1 like · 2,802 followersView post →
Pyydä Wegovy resepti.
Halvempi, vähemmän sivuvaikutuksia!
Mounjaro = Tirzepatide.
Tirzepatide group reported more serious adverse events (5-7% VS 3%) and higher #discontinuation rates due to adverse events (6-8.5% VS 4%)
https://t.co/5gP2zGE16d
https://t.co/ntZmKn4nmo
-
@paulcerro There’s some indication in the initial non inferiority study for a potentially superior effect, although that study was likely not designed for that purpose https://t.co/Fe5tc3Qw82
So that’s not so new after all
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/k0fJWHxUHA
Jul 17, 2024 · 1 like · 4,668 followersView post →
EZ
Evan Zeitler
@LittleBigGloms · X
@fperrywilson @Medscape It's an interesting analysis, but we actually did get this RCT in the diabetes population, which suggested that tirzepatide is more effective (even at low dose). Slightly different population, granted, but also high level evidence
https://t.co/3Pcp0FhR5w
@mackinprof GLP1a versus VLCD?
Context:
Very true for obesity.
But type 2 diabetes?
OBESITY
-Low Carb: https://t.co/O89rFEmWfr (~10%)
-TRZ: https://t.co/wvEdk27w1l (~21%)
T2D
-Low Carb: https://t.co/kQ9ZHaVjoo (12%)
-TRZ: https://t.co/Bmm3UCYlCM (12%)
I am sure as GLP1a https://t.co/D48bDGQBfR
RT @BowTied_MD: So true - studies show mounjaro/tirzepatide trumps ozempic/semaglutide when it comes to weight loss
In this study it was…
Jun 19, 2024 · 2 shares · 232,325 followersView post →
BP
BowTiedLoon | Degen Island Physician
@BowTiedLoon · X
RT @BowTied_MD: So true - studies show mounjaro/tirzepatide trumps ozempic/semaglutide when it comes to weight loss
In this study it was…
Jun 19, 2024 · 2 shares · 10,948 followersView post →
BM
BowTied MD
@BowTied_MD · X
So true - studies show mounjaro/tirzepatide trumps ozempic/semaglutide when it comes to weight loss
In this study it was virtually twice as effective
https://t.co/VaO7xTNKdv https://t.co/W29o6pLGti https://t.co/aMsxlz6bCw
Jun 19, 2024 · 11 likes · 2 shares · 643 followersView post →
MU
MD Ukulele
@benjy_md · X
i know im a bit late.. but i just wanna highlight the pharmacology of Tirzepatide here... Trial dated 2021 NEJM
https://t.co/KoHHbZl2bw
Mar 22, 2024 · 2 likes · 1,297 followersView post →
New “Once a Week” Drug | More Effective than Ozempic for Weight Loss (Tirzepatide/Mounjaro)
https://t.co/tfCras9WyC
#mounjaro #Ozempic #Semaglutide #Tirzepatide #livelonger #livelong #healthylifestyle #healthyliving #healthylife #healthy #biohacking #weightloss https://t.co/7mJKIND57E
5/ Unfortunately shortage of GLP1s, concerns w/ compounded semaglutide.
Hold GLP-1 day prior if daily, wk prior if wkly per ASA guidelines: https://t.co/PODj7Cc9aS
Tirzepatide is dual GLP1/GIP receptor agonist: no nausea & improved DM control & wt loss: https://t.co/ETsn1JsSmQ
Sep 28, 2023 · 1 like · 1,308 followersView post →
DG
Dra Ana Gabriela Garcia
@kokamosita · X
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/YZmdcaEViu
Tirzapatide 5/10/15 mg superior to Sema 1mg for Hba1c and weight reduction in this unblinded 40 week trial - lilly funded.
https://t.co/AIszfJLnYD
May 3, 2023 · 5 likes · 2 shares · 772 followersView post →
SP
Sai P Pydi
@saip_pydi · X
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/oPB1lJc4nJ
May 2, 2023 · 4 likes · 1 share · 646 followersView post →
DD
Daniel J Drucker
@DanielJDrucker · X
@NeilFlochMD A mostly very good summary except for “There are no head-to-head studies comparing semaglutide and tirzepatide” SURPASS-2 is H2H #T2D
https://t.co/4mdsFCLrU2
May 2, 2023 · 25 likes · 1 share · 34,083 followersView post →
TK
Ted Kyle
@ConscienHealth · X
RT @LittleBigGloms: @juliaoftoronto What about this? Direct comparison in T2DM. Tirzepatide works better. Why it works better is a more int…
One large RCT has shown that 5mg, 10mg, and 15mg of tirzepatide are more effective for weight loss and blood sugar than 1mg semaglutide (Ozempic)
It had a slightly worse safety profile - but both drugs had <10% cessation due to side effects
@juliaoftoronto What about this? Direct comparison in T2DM. Tirzepatide works better. Why it works better is a more interesting question.
(I love both, to be fair)
https://t.co/3Pcp0FhR5w
En #surpass trial 19-46% of pp w #T2D achieved “normal HbA1C” < 5.7%
https://t.co/S23aeoGaAc
Apr 6, 2023 · 1 like · 1 share · 1,100 followersView post →
SP
Simon Hodes, General Practitioner
@DrSimonHodes · X
@pash22 @novonordisk @Reuters @NICEComms @PharmRJ @susan_bewley Good Q)
A) Weight gain
We were discussing today at a CPD event
Look out for #Tirzepatide the new GIP-GLP1 coming next...
GIP = glucose-dependent insulinotropic polypeptide
Mar 15, 2023 · 16 shares · 146 followersView post →
RR
Robbie Puddick (MSc, RNutr)
@RPuddick · X
There were more deaths in the Tirzepatide group compared to semaglutide (12 vs 1)
But these weren't considered by the investigators to be linked to the administration of either medication
Full paper here: https://t.co/bvainBsfQL
Here is the link to the actual study.
In my dream world each of these would be OTC, and affordable, but that is about as likely to happen as the AMA/Congress/President looking out for something other then how to buy a new yacht every other year.
https://t.co/IPmOBSp6mr
@ncsvedberg Jo, de studier som finns idag är antingen utförda med doser som inte riktigt kan jämföras https://t.co/EW7gfxRSYP
Eller så får man jämföra mellan studier vilket är knepigt då det är så stor viktnedgång så resultatet blir beroende av hur mycket vikt som finns att förlora https://t.co/PeKMe6PYi9
RT @RahulDBarmanray: Tirzepatide even outperforms semaglutide, the current new hotness in diabetes and medical weight reduction therapies!…
Oct 24, 2022 · 1 share · 5,527 followersView post →
DB
Dr Rahul D Barmanray
@RahulDBarmanray · X
Tirzepatide even outperforms semaglutide, the current new hotness in diabetes and medical weight reduction therapies!
#ADATS22
9/...
https://t.co/KCg8n76L9X https://t.co/aonRhPWFlX
Oct 20, 2022 · 1 like · 1 share · 380 followersView post →
AA
A n b a r Aldawsari
@pharmproff · X
In patients with DM type2, tirzepatide was noninferior and superior to semaglutide with Hgb A1c respect to the mean change in the level from baseline to 40 weeks https://t.co/sZnZiDrv27
8/ Reductions in body weight were dose-dependent and did NOT seem to plateau at 40 weeks. Crazy!
https://t.co/gzE94EWdwK
But are they comparing
Aug 24, 2022 · 10 likes · 10,994 followersView post →
MM
Melina Manolas, MD, MPH
@melina_manolas · X
7/ What was the impact on A1c?
https://t.co/gzE94EE4iC
Tirzepatide appears to dramatically reduce A1c WITHOUT increasing risk of clinically significant hypoglycemia. https://t.co/YlqXLPGqsH
Aug 24, 2022 · 7 likes · 10,994 followersView post →
@Maabigo Beste Linda: semaglutide bestaat al langer, we weten dus beter wat het doet, maar je valt er minder van af dan van het nieuwe middel tirzepatide. Overigens verwacht ik dat er ooit nòg krachtiger middelen komen. Zo gaat het meestal. https://t.co/QeoXcy53B3.
RT @BevTchangMD: Patient Q: "If I can't take Ozempic bc of side effects, will I be able to take Mounjaro?"
Here's a winning evidence base…
May 31, 2022 · 2 shares · 2,332 followersView post →
EM
Elisa Haas, MD
@ElisaAHaas · X
RT @BevTchangMD: Patient Q: "If I can't take Ozempic bc of side effects, will I be able to take Mounjaro?"
Here's a winning evidence base…
May 31, 2022 · 2 shares · 445 followersView post →
BM
Beverly G. Tchang, MD
@BevTchangMD · X
Patient Q: "If I can't take Ozempic bc of side effects, will I be able to take Mounjaro?"
Here's a winning evidence based answer from @karlnadolsky showing comparable rates of side effects and numerically higher rate of discontinuation with Mounjaro:
https://t.co/WleAIGUYcP https://t.co/gPj5lvTbsx
May 31, 2022 · 7 likes · 2 shares · 6,106 followersView post →
MB
Myriam Beaulieu
@DraMyriambo10 · X
RT @redGDPS: Segunda bibliografia de apoyo:
Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus Semagluti…
May 29, 2022 · 3 shares · 394 followersView post →
I
IGOARANBA
@IGOARANBAR · X
RT @redGDPS: Segunda bibliografia de apoyo:
Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus Semagluti…
May 26, 2022 · 3 shares · 1,760 followersView post →
AJ
Ana Piera #JuntosEsMasFacil
@ana_apiecar · X
RT @redGDPS: Segunda bibliografia de apoyo:
Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus Semagluti…
May 25, 2022 · 3 shares · 2,574 followersView post →
RD
redGDPS Diabetes
@redGDPS · X
Segunda bibliografia de apoyo:
Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. https://t.co/wboPHzWUm2
May 25, 2022 · 6 likes · 3 shares · 15,487 followersView post →
DD
Dr Marian Dover
@DoverMarian · X
Looks like there will be a new kid on the weight loss and glycemic control block, outperforming ozempic.
Keen to watch this space.
#obesity #diabetes #MedTwitter
https://t.co/3zJUwhw0Co
May 14, 2022 · 1 like · 5,670 followersView post →
https://t.co/bdKiIw7DmS
للأطباء المهتمين بالعقار الجديد هنا بعض التفاصيل ومقارنة مع أحد أهم العقاقير المشابهة لحد ٍ ما لعلاج #السكري النوع الثاني https://t.co/1MY6wjEYme
May 13, 2022 · 1 like · 1 share · 15,617 followersView post →
عا
عمر منصور النزهة
@omarnozha · X
@sarah_bahowerth https://t.co/bdKiIw7DmS
May 13, 2022 · 1 like · 15,617 followersView post →
SL
Simon L
@SnupSnus · X
@CaloriesProper So yes GIP- I meant is the better glycemic control in https://t.co/pmNqxQpRTA
due to GIP effects or due to it being a more poten GLP-1 agonist? I don't follow diabetis very closely, it's all big pharma, and I don't know anyone with diabetis... In any case the only drugs
A dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, tirzepatide, was non-inferior or superior in glycemic control and weight reduction than with semaglutide in 40-week trial (N=469/group).
DOI: 10.1056/NEJMoa2107519
#diabetes #insulin https://t.co/3Vzk8ByKtt
The coming adjuvant therapy for recalcitrant obesity.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/meHFfqzfMH
@skathire @DrNadolsky @LillyPad Order of magnitude difference from this 40 week study showing 5.5kg weight loss on 15mg tirzepatide. Head scratcher. https://t.co/VyYVMOOgHu
Apr 28, 2022 · 1 like · 1,808 followersView post →
RT @redGDPS: #SURPASS2: Con TZP reducción HbA1c 5.82% vs #SEMA 6.42%. El 51% de los sujetos con TZP 15 mg alcanzaron la normoglucemia.
VE…
Oct 3, 2021 · 3 shares · 4,164 followersView post →
RD
redGDPS Diabetes
@redGDPS · X
#SURPASS2: Con TZP reducción HbA1c 5.82% vs #SEMA 6.42%. El 51% de los sujetos con TZP 15 mg alcanzaron la normoglucemia.
VER https://t.co/Z8366r6RB5
#EASD2021 @carlos_teixi
https://t.co/wboPHzWUm2 https://t.co/n8KMtLWdQw
Oct 3, 2021 · 3 likes · 3 shares · 15,487 followersView post →
鯵C
鯵ゼミ_Journal Club
@AJSR_since2005 · X
#064
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
N Engl J Med 2021;385:503-15.
SURPASS-2試験
2型糖尿病チルゼパチドはセマグルチドよりHbA1cを改善する
Tirzepatide is superior to Semaglutide on #A1c, #HDL, #TG and #weight. Limitations: short follow-up (actually 16 wks) and study population.
#MedEd
#Medtwitter
#Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/hBrsjjrDcs
SURPASS-2 [Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes] results out.. and as expected Tirzepatide (dual GIP-GLP1 receptor agonist) non-inferior and superior to Semaglutide in reducing HbA1c & body weight | NEJM https://t.co/Ni2V50jSe3
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/rUdsG6mZBq
Tirzepatide appears to be superior than Semaglutide on weight loss and HbA1c reductions
Trend new: Frías JP, ..., Surpass-2 Investigators (N Engl J Med) __Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes__
https://t.co/lpi5a8E3f8
RT @AmarPut: Exciting! Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - greater Hba1c lowering! #ADA2021 @drpa…
Jun 28, 2021 · 15 shares · 98 followersView post →
AH
Ani de Hollanda
@anidehollanda · X
RT @ObesitySeen: "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes"
SURPASS-2: Estudio fase 3, 1879 pacientes co…
Jun 28, 2021 · 6 shares · 1,123 followersView post →
EP
Estrella Petrina
@mepetrina · X
RT @ObesitySeen: "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes"
SURPASS-2: Estudio fase 3, 1879 pacientes co…
Jun 28, 2021 · 6 shares · 433 followersView post →
AZ
Ana Zugasti
@ana_azugas · X
RT @ObesitySeen: "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes"
SURPASS-2: Estudio fase 3, 1879 pacientes co…
Jun 28, 2021 · 6 shares · 3,567 followersView post →
O
ObesitySEEN
@ObesitySeen · X
"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes"
SURPASS-2: Estudio fase 3, 1879 pacientes con DM 2, 40 semanas de duración: Tirzepatide a dosis de 5, 10 y 15 mg demuestra superioridad respecto a Semaglutide a dosis de 1 mg en disminución de HbA1c. https://t.co/xAil0Ha00v
Jun 27, 2021 · 10 likes · 6 shares · 5,158 followersView post →
RV
Raul Villar
@DrRaulvillar · X
RT @drleonjimenez: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/yZsOlEni3j. No coment
Jun 27, 2021 · 2 shares · 409 followersView post →
DK
David Kliff
@diabetic_invstr · X
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/PhBdbSSICg
Jun 27, 2021 · 2 likes · 1,228 followersView post →
SR
SFB/TRR205 - adrenal research
@adrenalresearch · X
RT @CristobMorales: https://t.co/hYHyW8HN02 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes @sociedadSEEN @este…
Jun 27, 2021 · 27 shares · 283 followersView post →
EC
Eduard Centeno
@segol60 · X
RT @CristobMorales: https://t.co/hYHyW8HN02 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes @sociedadSEEN @este…
Jun 27, 2021 · 27 shares · 409 followersView post →
MS
Manu Morales Sánchez
@Manugrillo2 · X
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/FeYAFufyEi
Good evidence of weight loss and HbA1c lowering with #Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 #Diabetes. https://t.co/UrUYYIrqKR
Jun 26, 2021 · 16 likes · 2 shares · 11,548 followersView post →
ML
María Lainez López
@MLainezLopez · X
RT @vic_pallares: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/5whMjWTfC3
Jun 26, 2021 · 3 shares · 755 followersView post →
SS
Shugo Sasaki
@shugosasaki · X
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/l35960ZADP
RT @AmarPut: Exciting! Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - greater Hba1c lowering! #ADA2021 @drpa…
Jun 25, 2021 · 15 shares · 3,297 followersView post →
UA
Umaira Aziz
@documi · X
RT @AmarPut: Exciting! Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - greater Hba1c lowering! #ADA2021 @drpa…
Jun 25, 2021 · 15 shares · 1,038 followersView post →
E
EASDelearning
@EASDelearning · X
RT @AmarPut: Exciting! Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - greater Hba1c lowering! #ADA2021 @drpa…
Jun 25, 2021 · 15 shares · 5,268 followersView post →
T
# | TikTok
TikTok
doi:10.1056/NEJMoa2107519. 4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205 ...
Школа борьбы с диабетом (@school.demicheva) - Facebook
Facebook
nejm.org/doi/pdf/10.1056/NEJMoa2107519 SURPASS-4: тирзепатид превосходит инсулина гларгин в плане снижения гликогемоглобина и массы тела: https://www.thelancet.
Dr. Héctor Meza Izquierdo Angiologo y Cirujano Vascular | Papantla
Facebook
org/10.1056/NEJMoa2107519 Zinman, B., Wanner, C., Lachin, J. M., et al. (2023). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes ...
doi:10.1056/nejmoa2107519. 7. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med ...
PP
DT
YE
쥬J
豊ザ
DE
ち
M
J菲